Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

Sung Hoon Sim; Jeong Eun Kim; Min Hwan Kim; Yeon Hee Park; Jee Hyun Kim; Koung Jin Suh; Su Jin Koh; Kyong Hwa Park; Myoung Joo Kang; Mi Sun Ahn; Kyoung Eun Lee; Hee Jun Kim; Hee Kyung Ahn; Han Jo Kim; Keon Uk Park; Jae Ho Byun; Jin Hyun Park; Gyeong Won Lee; Keun Seok Lee; Joohyuk Sohn; Kyung Hae Jung; In Hae Park

doi:10.1016/j.breast.2022.08.002

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

Sung Hoon Sim
, Jeong Eun Kim
, Min Hwan Kim
, Yeon Hee Park
, Jee Hyun Kim
, Koung Jin Suh
, Su Jin Koh
, Kyong Hwa Park
, Myoung Joo Kang
, Mi Sun Ahn
, Kyoung Eun Lee
, Hee Jun Kim
, Hee Kyung Ahn
, Han Jo Kim
, Keon Uk Park
, Jae Ho Byun
, Jin Hyun Park
, Gyeong Won Lee
, Keun Seok Lee
, Joohyuk Sohn

Kyung Hae Jung, In Hae Park

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

Original language	English
Pages (from-to)	172-178
Number of pages	7
Journal	Breast
Volume	65
DOIs	https://doi.org/10.1016/j.breast.2022.08.002
State	Published - Oct 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors

Keywords

Clinical trial
HER2 positive
Metastatic breast cancer
Trastuzumab biosimilar
ctDNA

Access to Document

10.1016/j.breast.2022.08.002

Fingerprint

Dive into the research topics of 'Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)'. Together they form a unique fingerprint.

Cite this

Sim, S. H., Kim, J. E., Kim, M. H., Park, Y. H., Kim, J. H., Suh, K. J., Koh, S. J., Park, K. H., Kang, M. J., Ahn, M. S., Lee, K. E., Kim, H. J., Ahn, H. K., Kim, H. J., Park, K. U., Byun, J. H., Park, J. H., Lee, G. W., Lee, K. S., ... Park, I. H. (2022). Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B). Breast, 65, 172-178. https://doi.org/10.1016/j.breast.2022.08.002

@article{7a9fe002786c4f7ba81003e3430d8b4f,

title = "Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma{\textregistered}) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)",

abstract = "We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma{\textregistered}, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.",

keywords = "Clinical trial, HER2 positive, Metastatic breast cancer, Trastuzumab biosimilar, ctDNA",

author = "Sim, \{Sung Hoon\} and Kim, \{Jeong Eun\} and Kim, \{Min Hwan\} and Park, \{Yeon Hee\} and Kim, \{Jee Hyun\} and Suh, \{Koung Jin\} and Koh, \{Su Jin\} and Park, \{Kyong Hwa\} and Kang, \{Myoung Joo\} and Ahn, \{Mi Sun\} and Lee, \{Kyoung Eun\} and Kim, \{Hee Jun\} and Ahn, \{Hee Kyung\} and Kim, \{Han Jo\} and Park, \{Keon Uk\} and Byun, \{Jae Ho\} and Park, \{Jin Hyun\} and Lee, \{Gyeong Won\} and Lee, \{Keun Seok\} and Joohyuk Sohn and Jung, \{Kyung Hae\} and Park, \{In Hae\}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = oct,

doi = "10.1016/j.breast.2022.08.002",

language = "English",

volume = "65",

pages = "172--178",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

Sim, SH, Kim, JE, Kim, MH, Park, YH, Kim, JH, Suh, KJ, Koh, SJ, Park, KH, Kang, MJ, Ahn, MS, Lee, KE, Kim, HJ, Ahn, HK, Kim, HJ, Park, KU, Byun, JH, Park, JH, Lee, GW, Lee, KS, Sohn, J, Jung, KH & Park, IH 2022, 'Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)', Breast, vol. 65, pp. 172-178. https://doi.org/10.1016/j.breast.2022.08.002

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B). / Sim, Sung Hoon; Kim, Jeong Eun; Kim, Min Hwan et al.
In: Breast, Vol. 65, 10.2022, p. 172-178.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

AU - Sim, Sung Hoon

AU - Kim, Jeong Eun

AU - Kim, Min Hwan

AU - Park, Yeon Hee

AU - Kim, Jee Hyun

AU - Suh, Koung Jin

AU - Koh, Su Jin

AU - Park, Kyong Hwa

AU - Kang, Myoung Joo

AU - Ahn, Mi Sun

AU - Lee, Kyoung Eun

AU - Kim, Hee Jun

AU - Ahn, Hee Kyung

AU - Kim, Han Jo

AU - Park, Keon Uk

AU - Byun, Jae Ho

AU - Park, Jin Hyun

AU - Lee, Gyeong Won

AU - Lee, Keun Seok

AU - Sohn, Joohyuk

AU - Jung, Kyung Hae

AU - Park, In Hae

PY - 2022/10

Y1 - 2022/10

N2 - We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

AB - We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

KW - Clinical trial

KW - HER2 positive

KW - Metastatic breast cancer

KW - Trastuzumab biosimilar

KW - ctDNA

UR - https://www.scopus.com/pages/publications/85136302494

U2 - 10.1016/j.breast.2022.08.002

DO - 10.1016/j.breast.2022.08.002

M3 - Article

C2 - 36029565

AN - SCOPUS:85136302494

SN - 0960-9776

VL - 65

SP - 172

EP - 178

JO - Breast

JF - Breast

ER -